Rognan Ligand Design for G Protein-coupled Receptors

1. Auflage 2006
ISBN: 978-3-527-60826-3
Verlag: Wiley-VCH
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, Band 30, 264 Seiten, E-Book

Reihe: Methods and Principles in Medicinal Chemistry

G protein-coupled receptors (GPCRs) are one of the most important target classes in pharmacology and are the target of many blockbuster drugs. Yet only with the recent elucidation of the rhodopsin structure have these receptors become amenable to a rational drug design.
Based on recent examples from academia and the pharmaceutical industry, this book demonstrates how to apply the whole range of bioinformatics, chemoinformatics and molecular modeling tools to the rational design of novel drugs targeting GPCRs.
Essential reading for medicinal chemists and drug designers working with this largest class of drug targets in the human genome.

Autoren/Hrsg.

Rognan, Didier

Weitere Mitwirkende

Mannhold, Raimund

Kubinyi, Hugo

Folkers, Gerd

Inhaltsverzeichnis

GPCRs in the human genome
GPCR Three-dimensional structures: from bovine rhodopsin to homology models
Orphan GPCRs and ligand design
GPCR databases: From genes to proteins, from proteins to ligands
Druggability of human GPCRs
Molecular Mechanisms of GPCR activation & Oligomerisation
Allosteric regulation of GPCRs
Ligand-Based rational design
Receptor-based rational design
Chemogenomics approaches to ligand design and target priorisation
GPCR targeted libraries and privileged structures

Über Autor(innen)

Didier Rognan leads the Drug Bioinformatics Group at the Laboratory for Molecular Pharmacochemistry in Illkirch (France). He obtained a graduate degree in Pharmacy from the University of Rennes and completed his PhD in Medicinal Chemistry at the University of Strasbourg under the supervision of Camille G. Wermuth in 1989. Moving to the Swiss Federal Institute of Technology in Zürich he became Assistant Professor at the ETH before being named a research director at the CRNS in Illkirch near Strasbourg in 2000.
Professor Rognan is mainly interested in all aspects (method development, applications) of protein-based drug design and virtual screening.